$247 Million is the total value of Tri Locum Partners LP's 73 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -711,798 | -100.0% | -0.17% | – |
| Exit | ARCELLX INC | $0 | – | -42,826 | -100.0% | -0.22% | – | |
| FGEN | Exit | FIBROGEN INC | $0 | – | -74,348 | -100.0% | -0.26% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -214,661 | -100.0% | -0.62% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -36,460 | -100.0% | -0.65% | – |
| INSP | Exit | INSPIRE MED SYS INC | $0 | – | -23,412 | -100.0% | -1.14% | – |
| Exit | VENTYX BIOSCIENCES INC | $0 | – | -125,000 | -100.0% | -1.20% | – | |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $0 | – | -683,613 | -100.0% | -1.51% | – |
| NTRA | Exit | NATERA INC | $0 | – | -129,955 | -100.0% | -1.56% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INC | $0 | – | -636,943 | -100.0% | -1.68% | – |
| MRVI | Exit | MARAVAI LIFESCIENCES HLDGS I | $0 | – | -280,811 | -100.0% | -1.97% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -123,599 | -100.0% | -2.00% | – |
| ALLO | Exit | ALLOGENE THERAPEUTICS INC | $0 | – | -784,133 | -100.0% | -2.32% | – |
| SKIN | Exit | THE BEAUTY HEALTH COMPANY | $0 | – | -825,109 | -100.0% | -2.67% | – |
| Exit | BAUSCH PLUS LOMB CORP | $0 | – | -700,525 | -100.0% | -2.95% | – | |
| GSK | Exit | GSK PLCsponsored adr | $0 | – | -409,503 | -100.0% | -3.31% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -171,082 | -100.0% | -3.88% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -106,528 | -100.0% | -3.90% | – |
| CTLT | Exit | CATALENT INC | $0 | – | -235,320 | -100.0% | -4.67% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -30,115 | -100.0% | -5.69% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -196,390 | -100.0% | -5.72% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -90,551 | -100.0% | -6.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 10 | Q3 2023 | 0.5% |
| REGENERON PHARMACEUTICALS | 9 | Q3 2023 | 13.8% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| XENON PHARMACEUTICALS INC | 8 | Q3 2023 | 2.4% |
| ARGENX SE | 7 | Q3 2023 | 12.8% |
| STEVANATO GROUP S P A | 7 | Q2 2023 | 5.8% |
| PROTAGONIST THERAPEUTICS INC | 7 | Q2 2023 | 7.1% |
| AVADEL PHARMACEUTICALS PLC | 7 | Q3 2023 | 6.4% |
| BELLUS HEALTH INC NEW | 7 | Q3 2022 | 4.3% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.